David Peinsipp

Cooley advised the underwriters on the $250.1 million initial public offering of Neumora Therapeutics, a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed.

Cooley advised Acelyrin, INC., a late-stage biopharmaceutical company, in its $621 million initial public offering, the second-largest biotechnology IPO and largest clinical-stage biotechnology IPO ever.

Cooley advised the underwriters in LumiraDx Limited’s $100.3 million aggregate financing, consisting of (1) a $75.3 million follow-on offering of 43,000,000 shares of common stock at a public offering price of $1.75 per share and (2) a $25.0 million concurrent private placement with the Bill & Melinda Gates Foundation. LumiraDx is a diagnostics company manufacturing and commercializing an innovative diagnostic platform that supports a broad menu of tests with lab-comparable performance at the point of care. Partners Denny Won, Kristin VanderPas, Charlie Kim and Dave Peinsipp led the Cooley team.

Cooley advised the underwriters in Arcutis Biotherapeutics’ $172.5 million follow-on offering of 8,625,000 shares of common stock at a public offering price of $20.00 per share. Arcutis is a biopharmaceutical company developing and commercializing innovative treatments for immuno-dermatological diseases. Partners Denny Won, Kristin VanderPas, Charlie Kim and Dave Peinsipp led the Cooley team.

Cooley advised the underwriters in Pliant Therapeutics’ $230.0 million follow-on offering of 12,432,432 shares of common stock at a public offering price of $18.50 per share. Pliant is a clinical-stage biotechnology company discovering and developing novel therapies for the treatment of fibrosis. Partners Denny Won, Charlie Kim, Kristin VanderPas and Dave Peinsipp led the Cooley team.